SURE — Surenano Science Income Statement
0.000.00%
- CA$4.30m
- CA$4.23m
- 34
- 22
- 74
- 39
Annual income statement for Surenano Science, fiscal year end - March 31st, CAD millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.036 | 0.018 | 0 | 0 | 0 |
| Cost of Revenue | |||||
| Gross Profit | 0.026 | 0.012 | 0 | — | — |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 0.118 | 1.14 | 0.384 | 0.28 | 0.06 |
| Operating Profit | -0.082 | -1.12 | -0.384 | -0.28 | -0.06 |
| Gain / Loss on Sale of Assets | |||||
| Net Income Before Taxes | -0.082 | -1.12 | -0.384 | -0.28 | -0.06 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -0.083 | -1.12 | -0.384 | -0.28 | -0.06 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.083 | -1.12 | -0.384 | -0.28 | -0.06 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.083 | -1.12 | -0.384 | -0.28 | -0.06 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.004 | -0.055 | -0.018 | -0.013 | -0.011 |
| Dividends per Share |